Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 14 de 14
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Tipo de documento
Intervalo de ano de publicação
1.
Protein Expr Purif ; 141: 1-6, 2018 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-28843507

RESUMO

Metal-dependent lysine deacetylases (KDACs) are involved in regulation of numerous biological and disease processes through control of post-translational acetylation. Characterization of KDAC activity and substrate identification is complicated by inconsistent activity of prepared enzyme and a range of multi-step purifications. We describe a simplified protocol based on two-step affinity chromatography. The purification method is appropriate for use regardless of expression host, and we demonstrate purification of several representative members of the KDAC family as well as a selection of mutated variants. The purified proteins are highly active and consistent across preparations.


Assuntos
Cobalto/metabolismo , Histona Desacetilases/isolamento & purificação , Histona Desacetilases/metabolismo , Proteínas Repressoras/isolamento & purificação , Proteínas Repressoras/metabolismo , Animais , Dicroísmo Circular , Cobalto/química , Eletroforese em Gel de Poliacrilamida , Escherichia coli/genética , Histona Desacetilases/química , Histona Desacetilases/genética , Humanos , Proteínas Recombinantes/química , Proteínas Recombinantes/genética , Proteínas Recombinantes/isolamento & purificação , Proteínas Recombinantes/metabolismo , Proteínas Repressoras/química , Proteínas Repressoras/genética , Células Sf9/metabolismo
2.
Sex Med Rev ; 2024 Aug 09.
Artigo em Inglês | MEDLINE | ID: mdl-39122239

RESUMO

INTRODUCTION: Testicular prosthesis can be placed at the time of orchiectomy for many benign and malignant testicular conditions. The American Urological Association guidelines recommend discussing the implant prior to the procedure. OBJECTIVES: We review the literature on testicular prosthesis placement with respect to the history, psychological impact, surgical technique, complications, satisfaction, and novel emerging medical implications. METHODS: A Medline search was conducted with several terms related to and including "testicular implant," "testicular prosthesis," "testicular implant satisfaction," and "testicular implant history." Twenty articles were identified with patient satisfaction data. Satisfaction with the comfort, shape, size, and weight was reported in addition to satisfaction with the device from 13 studies. RESULTS: Overall satisfaction of testicular prosthesis is reported as high. Patients should be offered an implant at the time of orchiectomy or at any subsequent time based on their preference. CONCLUSION: This article presents a contemporary and comprehensive review of the literature on testicular prostheses. Satisfaction rates following implantation remain consistently high. Additionally, innovative approaches are being investigated, including the exploration of novel implants for treating hypogonadism. Moreover, the utilization of 3-dimensional printing technology is revolutionizing the creation of testicular implants, aiming to achieve a texture and density closely resembling human testicles.

3.
Transl Androl Urol ; 13(8): 1628-1640, 2024 Aug 31.
Artigo em Inglês | MEDLINE | ID: mdl-39280674

RESUMO

Background and Objective: Penile prostheses are an option for the management of erectile dysfunction (ED). Over the years penile prosthesis surgery has become increasingly safe owing to improvements such as antibiotic usage, coated devices, and surgical techniques. However, infection remains a dreaded complication during prosthesis surgery. Efforts to minimize risk of infection in the perioperative period have been extensively studied. Herein, we performed a narrative review on preoperative, intraoperative, and postoperative strategies for infection prevention during placement of a penile prosthesis with a comparison of infection prevention strategies to other surgical fields. Methods: A literature review was performed using PubMed and Google Scholar. Studies evaluating perioperative management of penile prosthesis infection were included. The following search terms were used to for our literature search: penile prosthesis, inflatable penile prosthesis, infection, prevention, perioperative management. Articles were graded based on the 2011 Oxford Centre for Evidence Based Medicine (OCEBM) guidelines and a table was generated with each intervention discussed and its level of evidence based on current literature. Key Content and Findings: Optimization of patient's comorbid conditions can help reduce risk during prosthesis operations. Monitoring and optimizing a patient's glycemic control has been investigated, but the current literature does not necessarily support a strict hemoglobin A1c (HbA1c) or pre-operative blood glucose level. Surgical field preparation using chlorhexidine-based solutions has been shown to be superior to iodine-based solutions. Appropriately selected peri-operative antibiotics have also been shown to reduce infection risk. Intraoperatively, the use of coated devices in addition to a 'no touch' technique have been shown to significantly reduce the risk of inflatable penile prosthesis (IPP) infection. Post operatively, available evidence of antibiotic use has not been demonstrated to be effective in reducing infection rates. Conclusions: Surgical infection following placement of an IPP is a devastating and morbid complication with infection rate up as high as 1-3% in virgin cases and 7-18% in revision cases. While perioperative techniques exist and have reduced risk of infection, more prospective data is needed to evaluate the clinical significance of these different approaches. More research in these areas, along with future options such as nanoparticles, antibiotic coated suture, and next generation sequencing (NGS) for bacterial pathogens, may shed light on further ways to optimize infection reduction strategies for prosthesis surgery.

4.
Urol Clin North Am ; 50(4): 531-539, 2023 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-37775212

RESUMO

While diversity and inclusion efforts have increased in urology, comparative analysis of personal statements from 2016-2017 and 2022-2023 residency applications showed few linguistic changes over time by gender or race/ethnicity. These results suggest the need for directed efforts to engage, mentor, and coach females and underrepresented minorities during medical school and the urology application process.


Assuntos
Internato e Residência , Urologia , Feminino , Humanos , Urologia/educação , Linguística , Grupos Minoritários
5.
Curr Probl Cancer ; 47(3): 100958, 2023 06.
Artigo em Inglês | MEDLINE | ID: mdl-37084464

RESUMO

To determine the distribution of race and ethnicity among genitourinary oncology trial participants leading to FDA approval of novel molecular entities/biologics. Secondarily, we evaluated whether the proportion of Black participants in clinical trials increased over time. We quired the FDA Center for Drug Evaluation and Research Drug Trials Snapshot (DTS) between 2015 and 2020 for urologic oncology clinical trials leading to FDA approval of novel drugs. Enrollment data was stratified by race and ethnicity. Cochran-Armitage Trend tests were used to examine changes in Black patient participation over years. Nine clinical trials were identified that led to FDA approval of 5 novel molecular entities for prostate and 4 molecular entities for urothelial carcinoma treatment. Trials for prostate cancer included 5202 participants of which 69.8% were White, 4.0% Black, 11.0% Asian, 3.6% Hispanic, <1% American Indian/Alaska Native or Native Hawaiian/Pacific Islander, 3% other. Trials in urothelial carcinoma had 704 participants of which 75.1% were male, 80.8% White, 2.3% Black, 2.4% Hispanic, <1% American Indian/Alaska Native or Native Hawaiian/Pacific Islander, 5% other. Black participation rates over time did not change for urothelial (P = 0.59) or the combined cancer cohort (P = 0.29). Prostate cancer enrollment trends among Black participant declined over time (P = 0.03). Participants in genitourinary clinical trials leading to FDA approval of novel drugs are overwhelmingly white. Involving stakeholders who represent the needs and interests of underrepresented populations in the design and implementation of clinical trials of novel agents may be a strategy to increase diversity, equity, and inclusion among genitourinary clinical trials.


Assuntos
Carcinoma de Células de Transição , Neoplasias da Próstata , Neoplasias da Bexiga Urinária , Humanos , Masculino , Diversidade, Equidade, Inclusão , Aprovação de Drogas , Avaliação de Medicamentos , Neoplasias da Próstata/tratamento farmacológico , Estados Unidos , Feminino , Ensaios Clínicos como Assunto
6.
Urology ; 162: 121-127, 2022 04.
Artigo em Inglês | MEDLINE | ID: mdl-34175332

RESUMO

OBJECTIVE: To address healthcare inequities, diversifying the physician workforce is an important step, and improved efforts to recruit Underrepresented in Medicine (URiM) students is vital. We aim to examine the current state of minority recruitment and provide solutions to increase diversity in urology residency training. METHODS: We conducted a retrospective analysis of self-reported race and ethnicity data for active urology trainees using the Data Resource Book by the Accreditation Council of Graduate Medical Education from 2011 to 2020. We also performed a longitudinal analysis comparing the number of urology applicants to urology trainees from 2016 to 2020 using the Electronic Residency Application Service statistics database. URiMs were designated in alignment with ACGME definitions. Categorical variables were summarized as frequencies and percentages and compared using chi-squared test between race and ethnicity. RESULTS: We identified 11,458 active urology trainees for analysis. Of these, 6638 (57.9%) identified as White, 1690 (14.7%) as Asian/Pacific Islander, 442 (3.9%) as Hispanic, 380 (3.3%) as Black, 11 (0.1%) as Native American, 608 (5.3%) as other race/ethnicity, and 1689 (14.7%) as unknown race or ethnicity. In 2011, 8.1% of trainees identified as URiM which remains the same at 8.2% in 2020. CONCLUSION: As we strive to improve patient care and support our URiM colleagues, diversity, equity, and inclusion must be prioritized. Despite increases in students entering medical school and the expansion of urology training spots, the numbers of URiM in urologic training remain stubbornly unchanged. This work highlights an area of residency training that requires critical transformation.


Assuntos
Urologia , Diversidade Cultural , Humanos , Grupos Minoritários/educação , Projetos Piloto , Estudos Retrospectivos
7.
Cancer Res ; 80(2): 249-262, 2020 01 15.
Artigo em Inglês | MEDLINE | ID: mdl-31744816

RESUMO

Beclin 1 has nonautophagic functions that include its ability to regulate endocytic receptor trafficking. However, the contribution of this function to tumor suppression is poorly understood. Here, we provide in vivo evidence that Beclin 1 suppresses tumor proliferation by regulating the endocytic trafficking and degradation of the EGFR and transferrin (TFR1) receptors. Beclin 1 promoted endosomal recruitment of hepatocyte growth factor tyrosine kinase substrate (HRS), which was necessary for sorting surface receptors to intraluminal vesicles for signal silencing and lysosomal degradation. In tumors with low Beclin 1 expression, endosomal HRS recruitment was diminished and receptor function was sustained. Collectively, our results demonstrate a novel role for Beclin 1 in impeding tumor growth by coordinating the regulation of key growth factor and nutrient receptors. These data provide an explanation for how low levels of Beclin 1 facilitate tumor proliferation and contribute to poor cancer outcomes. SIGNIFICANCE: Beclin 1 controls the trafficking fate of growth regulatory receptors to suppress tumor proliferation.


Assuntos
Proteína Beclina-1/metabolismo , Complexos Endossomais de Distribuição Requeridos para Transporte/metabolismo , Endossomos/metabolismo , Neoplasias/patologia , Fosfoproteínas/metabolismo , Antígenos CD/metabolismo , Linhagem Celular Tumoral , Proliferação de Células , Progressão da Doença , Receptores ErbB/metabolismo , Humanos , Receptores da Transferrina/metabolismo
8.
Nat Metab ; 2(7): 603-611, 2020 07.
Artigo em Inglês | MEDLINE | ID: mdl-32694795

RESUMO

The micronutrient selenium is incorporated via the selenocysteine biosynthesis pathway into the rare amino acid selenocysteine, which is required in selenoproteins such as glutathione peroxidases and thioredoxin reductases1,2. Here, we show that selenophosphate synthetase 2 (SEPHS2), an enzyme in the selenocysteine biosynthesis pathway, is essential for survival of cancer, but not normal, cells. SEPHS2 is required in cancer cells to detoxify selenide, an intermediate that is formed during selenocysteine biosynthesis. Breast and other cancer cells are selenophilic, owing to a secondary function of the cystine/glutamate antiporter SLC7A11 that promotes selenium uptake and selenocysteine biosynthesis, which, by allowing production of selenoproteins such as GPX4, protects cells against ferroptosis. However, this activity also becomes a liability for cancer cells because selenide is poisonous and must be processed by SEPHS2. Accordingly, we find that SEPHS2 protein levels are elevated in samples from people with breast cancer, and that loss of SEPHS2 impairs growth of orthotopic mammary-tumour xenografts in mice. Collectively, our results identify a vulnerability of cancer cells and define the role of selenium metabolism in cancer.


Assuntos
Inativação Metabólica , Neoplasias/metabolismo , Selênio/metabolismo , Sistema y+ de Transporte de Aminoácidos/metabolismo , Animais , Neoplasias da Mama/metabolismo , Neoplasias da Mama/patologia , Linhagem Celular Tumoral , Sobrevivência Celular , Feminino , Ferroptose , Humanos , Camundongos , Camundongos Nus , Neoplasias/patologia , Fosfolipídeo Hidroperóxido Glutationa Peroxidase/metabolismo , Fosfotransferases/metabolismo , Compostos de Selênio/metabolismo , Selenocisteína/metabolismo , Ensaios Antitumorais Modelo de Xenoenxerto
9.
Urol Pract ; 11(1): 76, 2024 01.
Artigo em Inglês | MEDLINE | ID: mdl-37914156
10.
PLoS One ; 14(8): e0220567, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-31393907

RESUMO

The insulin-like growth factor-1 (IGF-1) signaling pathway has been implicated in non-small cell lung cancer (NSCLC) outcomes and resistance to targeted therapies. However, little is known regarding the molecular mechanisms by which this pathway contributes to the biology of NSCLC. The insulin receptor substrate (IRS) proteins are cytoplasmic adaptor proteins that signal downstream of the IGF-1R and determine the functional outcomes of this signaling pathway. In this study, we assessed the expression patterns of IRS-1 and IRS-2 in NSCLC to identify associations between IRS-1 and IRS-2 expression levels and survival outcomes in the two major histological subtypes of NSCLC, adenocarcinoma (ADC) and squamous cell carcinoma (SCC). High IRS-2 expression was significantly associated with decreased overall survival in adenocarcinoma (ADC) patients, whereas low IRS-1 cytoplasmic expression showed a trend toward association with decreased overall survival in squamous cell carcinoma (SCC) patients. Tumors with low IRS-1 and high IRS-2 expression were found to be associated with poor outcomes in ADC and SCC, indicating a potential role for IRS-2 in the aggressive behavior of NSCLC. Our results suggest distinct contributions of IRS-1 and IRS-2 to the biology of ADC and SCC that impact disease progression.


Assuntos
Adenocarcinoma de Pulmão , Carcinoma Pulmonar de Células não Pequenas , Carcinoma de Células Escamosas , Proteínas Substratos do Receptor de Insulina/biossíntese , Neoplasias Pulmonares , Proteínas de Neoplasias/biossíntese , Adenocarcinoma de Pulmão/metabolismo , Adenocarcinoma de Pulmão/mortalidade , Adenocarcinoma de Pulmão/patologia , Adulto , Idoso , Carcinoma Pulmonar de Células não Pequenas/metabolismo , Carcinoma Pulmonar de Células não Pequenas/mortalidade , Carcinoma Pulmonar de Células não Pequenas/patologia , Carcinoma de Células Escamosas/metabolismo , Carcinoma de Células Escamosas/mortalidade , Carcinoma de Células Escamosas/patologia , Intervalo Livre de Doença , Feminino , Regulação Neoplásica da Expressão Gênica , Humanos , Neoplasias Pulmonares/metabolismo , Neoplasias Pulmonares/mortalidade , Neoplasias Pulmonares/patologia , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Taxa de Sobrevida
11.
JCI Insight ; 3(8)2018 04 19.
Artigo em Inglês | MEDLINE | ID: mdl-29669935

RESUMO

Pleomorphic invasive lobular carcinoma (PILC) is an aggressive variant of invasive lobular breast cancer that is associated with poor clinical outcomes. Limited molecular data are available to explain the mechanistic basis for PILC behavior. To address this issue, targeted sequencing was performed to identify molecular alterations that define PILC. This sequencing analysis identified genes that distinguish PILC from classic ILC and invasive ductal carcinoma by the incidence of their genomic changes. In particular, insulin receptor substrate 2 (IRS2) is recurrently mutated in PILC, and pathway analysis reveals a role for the insulin receptor (IR)/insulin-like growth factor-1 receptor (IGF1R)/IRS2 signaling pathway in PILC. IRS2 mutations identified in PILC enhance invasion, revealing a role for this signaling adaptor in the aggressive nature of PILC.


Assuntos
Carcinoma Lobular/genética , Proteínas Substratos do Receptor de Insulina/genética , Receptores de Somatomedina/genética , Idoso , Idoso de 80 Anos ou mais , Neoplasias da Mama/patologia , Carcinoma Lobular/patologia , Feminino , Humanos , Linfonodos/patologia , Pessoa de Meia-Idade , Mutação de Sentido Incorreto/genética , Invasividade Neoplásica/patologia , Estadiamento de Neoplasias , Receptor IGF Tipo 1 , Sequenciamento do Exoma/métodos
14.
Oncotarget ; 8(23): 36934-36935, 2017 Jun 06.
Artigo em Inglês | MEDLINE | ID: mdl-28455962
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA